ARCHIVES

Cephalon To Plead Guilty, Pay $425M For Off-Label Marketing.

This article is from The Cancer Letter archive.

Vol. 34 No. 36 | October 3, 2008

Download PDF Visit The Full Archive

Related Articles

Cancer Groups Urge FDA To Spell Out Standards For Data Collection In Time-To-Progression Trials.

November 7, 2008

16 Institutions Win NCI Awards for Phase I Trials

May 2, 2003

ORI Finds Misconduct By Two Researchers

December 8, 1995

Tykerb And Trastuzumab Showed Increase In PFS For HER2+ Breast Cancer In Study

May 30, 2008

Survivorship Studies Unfocused As Total Research Increases

November 25, 2011

Minority Based CCOP RFA Generate Wide Interest; 44 Letters Of Intent Received for Eight Awards

September 1, 1989